Compare CXM & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXM | TWST |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2021 | 2018 |
| Metric | CXM | TWST |
|---|---|---|
| Price | $6.65 | $41.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $9.89 | ★ $44.67 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 12-03-2025 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 180.38 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $839,147,000.00 | $376,572,000.00 |
| Revenue This Year | $8.25 | $15.19 |
| Revenue Next Year | $3.44 | $15.10 |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | 6.48 | ★ 20.32 |
| 52 Week Low | $6.62 | $23.30 |
| 52 Week High | $9.69 | $55.33 |
| Indicator | CXM | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 25.93 | 72.23 |
| Support Level | $7.17 | $34.55 |
| Resistance Level | $7.76 | $41.34 |
| Average True Range (ATR) | 0.25 | 1.98 |
| MACD | -0.11 | 0.70 |
| Stochastic Oscillator | 1.19 | 88.45 |
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.